Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu CP, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C.
Chen G, et al. Among authors: zhang l, zhang s, zhang y.
Ann Oncol. 2013 Jun;24(6):1615-22. doi: 10.1093/annonc/mdt012. Epub 2013 Mar 1.
Ann Oncol. 2013.
PMID: 23456778
Free article.
Clinical Trial.